MARKETS / NASDAQ / KRMD
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Koru Medical Systems, Inc. KRMD

15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$41.1M
▲ 22.2% vs FY2024
EPS · FY25
$-0.06
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-15.6%
Net margin · FY25
-6.4%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 41.1M
Revenue, FY2025 · full 15-year series below
Revenue Net income
0.020.040.060.0-0.0201020132016202020232025
0.020.040.060.0-0.02016202020232025

The company lost 6 cents on every revenue dollar this year.

Per share
USD -0.06
Diluted EPS, FY2025
EPS
0.40.81.2-0.06201020132016202020232025
0.40.81.2-0.062016202020232025

The company pays no cash dividend.

Profitability
-15.6%
Return on equity, FY2025
ROE
8162432-15.6%201020132016202020232025
8162432-15.6%2016202020232025
Operating margin-7.2%
Net margin-6.4%
Return on assets-9.5%

Each USD of equity lost 16 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+11.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+13.8%
+11.2%
+12.9%
+15.2%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.05B
Shares outstanding, FY2025
0.030.05201020132016202020232025
0.040.052016202020232025
Change, 5 years+7.2%
Change, 10 years+22.1%

The share count grew 7% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 28.2M
total assets, end of FY2025
Total assetsUSD 28.2M
EquityUSD 17.0M
CashUSD 8.9M
Current ratio2.44×

Equity funds 60% of total assets.

History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−0.06
−0.13
−0.30
−0.19
−0.10
−0.03
0.01
0.02
−0.01
0.02
0.02
0.02
0.02
0.02
0.02
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−15.6
−32.6
−53.2
−25.5
−12.6
−5.1
5.6
10.2
−7.8
11.7
13.1
14.7
18.4
27.1
28.4
Shares out B
0.05
0.05
0.05
0.05
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.03

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
57 of 57
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed